All Drug Discovery articles – Page 8
-
NewsNovel enzyme inhibitors exploits key weakness in malaria parasite
Researchers from the Universities of Bath and Leeds have engineered a novel class of aminopeptidase P inhibitors with enhanced binding affinity and antiparasitic activity against Plasmodium falciparum.
-
NewsBispecific antibody targets Wnt co-receptors for diabetic macular oedema treatment
Preclinical data presented at ARVO 2026 demonstrate therapeutic potential of targeting Gpr124 and Lrp6 Wnt co-receptors to restore blood-retina barrier integrity in diabetic macular oedema and wet age-related macular degeneration, with trispecific candidate NVQ501 advancing towards IND-enabling studies.
-
ReportOrganoids and Organ Chips: Improving Decision-Making in Early Drug Discovery
Traditional preclinical models do not always predict what will happen in patients. This report explores how organoids, organ-on-chip systems and advanced imaging are being used to generate more clinically relevant insights and support better decision-making earlier in drug discovery.
-
NewsSafer diazo compound synthesis advances medicinal chemistry capabilities
Researchers at Tokyo University of Science have developed a safer synthetic route to β-heteroatom-substituted diazo esters, eliminating the need for toxic diazomethane. The azide-to-diazo conversion method uses mild conditions and readily available starting materials, potentially streamlining early-stage drug discovery and compound library synthesis.
-
ArticleThe scale divide: competing strategies in AI drug discovery
Two approaches to AI in preclinical drug discovery are diverging, from multi-thousand GPU systems to models with only a handful of parameters, with early results raising questions about which will deliver.
-
NewsNew SEE-CITE technology maps drug-protein interactions with targeted precision
A UCLA-led research team has developed SEE-CITE, an advanced photo-crosslinking technology that enables direct comparison of drug-protein binding interactions, potentially aiding the discovery of safer, more effective therapeutics across multiple disease areas.
-
ArticleWhen scale meets insight: reinventing SPR for the future of drug discovery
Carterra’s new 48-channel SPR platform reimagines throughput, automation and data quality for modern discovery workflows.
-
NewsHybrid molecule shows enhanced metabolic effects in obesity study
A novel hybrid molecule combining incretin therapy with targeted intracellular delivery of a PPAR agonist has demonstrated strong weight loss and glucose control compared to existing GLP-1/GIP therapies in preclinical studies.
-
ArticleDrug Target Review launches new website designed for drug discovery professionals
Drug Target Review has launched an updated website to improve access to content across early-stage drug discovery, alongside a new membership model that offers a gateway to premium analysis, reports and expert commentary.
-
NewsAAX Biotech and evitria partner on antibody development
AAX Biotech has partnered with evitria AG to expand access to its Opti-mAb® platform, enabling earlier integration of stability-enhancing technology into antibody candidate design and multispecific format development.
-
NewsNew approach targets ‘undruggable’ proteins in prostate cancer
A novel drug design strategy has achieved binding strengths up to a million times greater than previous approaches against intrinsically disordered proteins, potentially leading to new treatments for prostate cancer and other diseases involving these historically intractable targets.
-
ArticleWhy lower organisms matter for neurodegeneration drug discovery
In the wake of recent government policy aimed at actively replacing animal models in drug discovery, we consider a possible solution to the translational shortfalls of current cellular methodologies for neurodegenerative disease.
-
NewsNew method streamlines C–N bond formation for amine synthesis
Researchers at the University of Wisconsin–Madison have reported a new approach to forming carbon–nitrogen bonds, a critical step in the synthesis of amines widely used in pharmaceuticals, agrochemicals and polymers.
-
ArticleFrom leaderboards to lab notebooks: AI designs reach preclinical testing
For years, AI drug discovery has been judged on benchmark performance. Now, a set of studies shows what happens when those designs are made and tested in preclinical settings.
-
ArticleVariant or viable target? How resolving complex genomic regions is reshaping rare disease therapeutics
Dr Aaron Wenger reveals how improvements in long-read sequencing technology is enabling the elucidation of complex disease mechanisms for targeted and effective treatments for rare diseases.
-
NewsOvarian follicles provide new platform for angiogenesis research
A novel microphysiological system using ovarian follicles enables physiologically relevant three-dimensional angiogenesis modelling within 24 hours, offering improved drug screening capabilities that distinguish therapeutic effects from general toxicity.
-
NewsNew platform reveals shared drug targets across genetic mutations in cancer and neurodegeneration
Researchers have developed PerturbFate, a platform that simultaneously tracks gene expression, RNA dynamics and chromatin accessibility across thousands of genetic perturbations in single cells. Applied to melanoma drug resistance, the technology revealed that diverse mutations converge on shared regulatory nodes, offering a route to therapies targeting common mechanisms rather than individual genetic alterations.
-
ArticleBeyond serendipity: rational design and AI’s expansion of the undruggable target landscape
For decades, drugging the ‘undruggable’ was thought to require luck rather than logic. Today, AI is transforming serendipity into strategy by enabling rational, data-driven approaches to previously inaccessible targets.
-
NewsAI platform models protein flexibility to accelerate drug design
A new artificial intelligence platform developed at the University of Virginia addresses a critical limitation in computational drug design by modelling protein flexibility during molecular interactions. The suite of tools uses diffusion models to generate drug candidates whilst accounting for induced fit dynamics, potentially improving success rates in early-stage development.
-
NewsELRIG launches inaugural US drug discovery conference 2026 in Cambridge, MA
ELRIG has announced Drug Discovery USA 2026, a free two-day conference at Pfizer Cambridge bringing together international researchers to address challenging therapeutic targets through advances in multifunctional small molecules and novel biologics.